Temozolomide SUN 180 mg hard capsules
Sponsors
Debiopharm International S.A., Bristol-Myers Squibb Services Unlimited Company, Institut De Recherches Internationales Servier IRIS, Helse Bergen HF, Universitair Medisch Centrum Utrecht
Conditions
Diffuse Midline GliomaGlioblastomaGrade IV recurrent glioma which includes both glioblastomaH3K27-alteredIDH1-mutant GliomaIDH2-mutant GliomaPan tumorclassified as IDH wt and grade IV IDH mutated astrocytoma.
Phase 1
A phase 1/2 open-label study of Debio 0123 in combination with temozolomide in adult participants with recurrent or progressive glioblastoma and of Debio 0123 in combination with temozolomide and radiotherapy in adult participants with newly diagnosed glioblastoma
RecruitingCTIS2022-502156-31-00
Start: 2023-05-26Target: 55Updated: 2025-11-03
BORTEZOMIB SENSITIZATION OF RECURRENT GRADE-4 GLIOMA WITH UNMETHYLATED MGMT PROMOTER TO TEMOZOLOMIDE. PHASE IB/II. (BORTEM 17)
RecruitingCTIS2024-515142-16-00
Start: 2024-10-03Target: 63Updated: 2024-10-02
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Active, not recruitingCTIS2024-513738-39-00
Start: 2025-03-18Target: 17Updated: 2025-12-18
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial
Not yet recruitingCTIS2025-520814-78-00
Target: 20Updated: 2026-03-23